Skip to main content
healthportal
SubscribeβŠ™Sign in
πŸ”12+ medical reviewers in networkπŸ†FDA & peer-reviewed sourcesπŸ“ˆUpdated weekly🩺Medically reviewed content

Newsletter

Weekly GLP-1 updates, no filler

Shortages, savings, new approvals, and reviewer-vetted guidance. 5 min/week.

Free Week-1 Survival Kit PDF on signupΒ· 5,400+ readers Β· weekly Β· unsubscribe anytime

healthportal

Evidence-based GLP-1 reviews. Medically reviewed, affiliate-funded, editorially independent.

Language

EnglishEspaΓ±ol

Compare providers

  • Best overall
  • Cheapest
  • Best rated
  • Accepts insurance
  • Most medications
  • Side-by-side

Medications

  • Wegovy
  • Ozempic
  • Zepbound
  • Mounjaro
  • Saxenda
  • Rybelsus
  • All medications

Tools

  • Match me to a provider
  • Eligibility checker
  • Weight-loss projection
  • PAP eligibility
  • Symptom triage
  • Insurance coverage
  • All tools

Coverage & savings

  • Insurance appeals
  • GLP-1 cost by state
  • Cost trends
  • Compounded vs brand
  • Switching guides
  • Shortage tracker
  • Drug pipeline

Research & editorial

  • Primary-data research
  • GLP-1 Diaries
  • News + recalls
  • Lawsuit + MDL tracker
  • Q&A library
  • Glossary
  • Editorial board
  • Editorial standards
  • Press kit

GLP-1 by audience

  • Sleep
  • Fitness
  • Mental health
  • Pediatric
  • Veterans
  • Medicare
  • Seniors
  • Men
  • Postmenopausal
  • Trans + gender-diverse
  • Post-bariatric

For informational purposes only. Not medical advice. Talk to a licensed clinician before starting, stopping, or switching medication. Β© 2026 Health Portal.

  • Medically reviewed
  • FDA + peer-reviewed
  • Updated weekly
  • Independent ranking
HomeTop picksMedsQuizSaved
HomeConditionsPolycystic ovary syndrome

ICD-10 Β· E28.2

Polycystic ovary syndrome(PCOS)

PCOS is the most common endocrine disorder in women of reproductive age, affecting roughly 8-13% globally. It is characterized by irregular menstrual cycles, excess androgens, and polycystic ovaries. GLP-1 medications are increasingly used off-label for the obesity and insulin-resistance components of PCOS.

Medically reviewed by Dr. Jane Novak, MD, MPH on June 1, 2026

Key takeaways

  • 1PCOS is the most common endocrine disorder in women of reproductive age, affecting roughly 8-13% globally. It is characterized by irregular menstrual cycles, excess androgens, and polycystic ovaries. GLP-1 medications are increasingly used off-label for the obesity and insulin-resistance components of PCOS.
  • 2Treatment options include Hormonal contraceptives, Metformin, Spironolactone (anti-androgen).
  • 3Key risk factors: Family history of PCOS, Insulin resistance, Obesity.

This is general health information, not medical advice. Talk to a licensed clinician about diagnosis and treatment options.

Overview

PCOS combines reproductive (irregular cycles, infertility), metabolic (insulin resistance, weight gain), and dermatologic (acne, hirsutism) features. The exact cause is unknown but involves insulin resistance and elevated androgens. Approximately 60-70% of women with PCOS have insulin resistance regardless of weight. GLP-1 receptor agonists are not FDA-approved specifically for PCOS but are increasingly prescribed off-label for PCOS-associated obesity and insulin resistance. Metformin remains the first-line metabolic treatment. A 2023 meta-analysis in *Reproductive BioMedicine Online* found semaglutide improved menstrual regularity and reduced free androgen index.

Symptoms

  • Irregular periods
  • Infertility
  • Acne and oily skin
  • Hirsutism (excess hair growth)
  • Weight gain
  • Hair thinning
  • Insulin resistance

Risk factors

  • Family history of PCOS
  • Insulin resistance
  • Obesity
  • Sedentary lifestyle

Treatment options

  • Hormonal contraceptives
  • Metformin
  • Spironolactone (anti-androgen)
  • GLP-1 receptor agonists (off-label)
  • Letrozole/clomiphene for fertility
  • Lifestyle intervention

GLP-1 evidence for polycystic ovary syndrome

Editorial grades summarizing study quality and convergence. How we grade.

ClaimGradeBasis

GLP-1 therapy improves insulin sensitivity in PCOS

Source: Reproductive Biology & Endocrinology, 2023

Small-to-medium RCTs (n<300 each) show improved HOMA-IR; no large definitive trial

BModerate evidenceSmall-to-medium RCTs (n<300 each) show improved HOMA-IR; no large definitive trial

GLP-1 weight loss restores ovulatory cycles in some patients

Observational + small trial data; ovulation rate ~30-50% higher than controls

BModerate evidenceObservational + small trial data; ovulation rate ~30-50% higher than controls

GLP-1 directly treats hyperandrogenism (acne, hirsutism)

Effect appears secondary to weight loss + insulin improvement, not androgen-specific

CLimited evidenceEffect appears secondary to weight loss + insulin improvement, not androgen-specific

GLP-1 is FDA-approved for PCOS

No FDA-approved indication for PCOS; use is off-label, weight-driven

FNo evidenceNo FDA-approved indication for PCOS; use is off-label, weight-driven

Related GLP-1 medications

Mounjaro

GIP/GLP-1 dual receptor agonist Β· ~$1023.04/mo

View details

Wegovy

GLP-1 receptor agonist Β· ~$1349.02/mo

View details

Ozempic

GLP-1 receptor agonist Β· ~$935.77/mo

View details

Not sure which medication is right for you? Our quiz matches you with providers based on state, insurance, and budget.

Take the GLP-1 quiz
People also ask

Common questions readers ask

Do I need to exercise on Wegovy?
Yes β€” resistance training specifically. Without it, 25-40% of weight lost on GLP-1 comes from lean muscle. Cardio is a bonus; resistance is the non-negotiable.
Full evidence-graded answer
How fast do results show on GLP-1?
Appetite changes in 1-2 weeks. Visible weight loss usually starts in week 4-6. Significant fat loss accelerates in weeks 12-44 as the dose escalates.
Full evidence-graded answer
Why am I not losing weight on Wegovy?
Most non-responders fall into 4 buckets: dose hasn't reached maintenance (2.4 mg), titration was interrupted, calorie intake creeps to match satiety, or a hormonal/medical confounder (hypothyroid, PCOS-with-insulin-resistance, sleep apnea). Talk to your prescriber if no measurable loss by week 16 at maintenance dose.
Full evidence-graded answer
Can I build muscle on a GLP-1?
Yes β€” with deliberate resistance training and adequate protein. Without it, 25-40% of weight lost on GLP-1 comes from lean muscle. Lifting 2-3x/week + 1.2-1.6 g/kg ideal-body-weight protein preserves and can grow muscle while losing fat.
Full evidence-graded answer
Can GLP-1 help with PCOS?
Yes β€” primarily via weight loss and improved insulin sensitivity. Smaller trials show improved ovulatory cycles and reduced androgen symptoms in women with PCOS. No GLP-1 is FDA-approved for PCOS; use is off-label and weight-driven.
Full evidence-graded answer
Does GLP-1 work for type 1 diabetes?
No GLP-1 is FDA-approved for type 1 diabetes. Some endocrinologists prescribe semaglutide off-label as an insulin adjunct in T1D with obesity or insulin resistance, but evidence is limited and DKA risk during gastric-emptying changes requires careful monitoring.
Full evidence-graded answer

Sources

  • International evidence-based guideline for PCOS β€” Monash University / Endocrine Society
  • GLP-1 receptor agonists in PCOS β€” Reproductive BioMedicine Online

Get the relevant updates

Pick the topic that matches what brought you here. One short email per week, no filler.

Pick a newsletter topic

No third-party ad trackers. Unsubscribe anytime β€” link in every email.

Was this page helpful?